AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
• Lactobacillus rhamnosus (Rh) and Lactobacillus reuteri (Re) showed intraspecific and interspecific specificity in relieving colitis.
• Re performed better than Rh overall in alleviating colitis.
• Rh was superior to Re in the synthesis of SCFAs.
• In the effective Rh and Re strains, carbohydrate metabolism- and prophage-related genes are prevalent, respectively.
Lactobacillus rhamnosus (Rh) and Lactobacillus reuteri (Re) are well-known probiotic species in inflammatory bowel disease (IBD) research. The variations between these species’ efficacy against colitis, and their model of action in this regard, are intriguing and enable treatment to be individually tailored to patients. In this study, four strains each of Rh and Re were isolated from fecal samples and their draft genomes were sequenced. The anti-colitis activities of both strains involved various aspects of intestinal immune, physical, chemical, and biological barrier function. Strikingly, the tested strains exhibited considerable interspecies and intraspecies specificity in colitis amelioration. Rh strains significantly outperformed Re strains in terms of short-chain fatty acid synthesis. Nevertheless, Re strains were more effective than Rh strains in inhibiting production of inflammatory factors; promoting production of intestinal mucus, antimicrobial peptides, and tight junction proteins; and supporting the stem cell compartment. This accounts for the anti-colitis outcomes of Re strains being superior to those of Rh strains. In addition, the effective Rh and Re strains were found to express high concentrations of specific carbohydrate metabolism- and prophage-related genes, respectively. Taken together, the results of this study could assist researchers in developing effective therapies for IBD.
D.C. Baumgart, S.R. Carding, Gastroenterology 1: inflammatory bowel disease: cause and immunobiology, Lancet 369 (2007) 1627-1640. https://doi.org/10.1016/S0140-6736(07)60750-8.
K. Hazel, A. O’Connor, Emerging treatments for inflammatory bowel disease, Ther. Adv. Chronic Dis. 11 (2020) 2040622319899297. https://doi.org/10.1177/2040622319899297.
M.F. Neurath, Current and emerging therapeutic targets for IBD, Nat. Rev. Gastroenterol. Hepatol. 14 (2017) 269-278. https://doi.org/10.1038/nrgastro.2016.208.
J.P. Gordon, P.C. McEwan, A. Maguire, et al., Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys, Eur. J. Gastroenterol. Hepatol. 27 (2015) 804-812. https://doi.org/10.1097/MEG.0000000000000378.
D. Turner, A. Ricciuto, A. Lewis, et al., STRIDE-Ⅱ: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD, Gastroenterology 160 (2021) 1570-1583. https://doi.org/10.1053/j.gastro.2020.12.031.
S. Danese, G. Roda, L. Peyrin-Biroulet, Evolving therapeutic goals in ulcerative colitis: towards disease clearance, Nat. Rev. Gastroenterol. Hepatol. 17 (2020) 1-2. https://doi.org/10.1038/s41575-019-0211-1.
D. Jakubczyk, K. Leszczynska, S. Gorska, The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)—a critical review, Nutrients 12 (2020) 1973. https://doi.org/10.3390/nu12071973.
Y. Liang, M. Liu, J. Pu, et al., Probiotics and their metabolites ameliorate inflammatory bowel disease: a critical review, Infect. Microbes Dis. 3 (2021) 4-13. https://doi.org/10.1097/IM9.0000000000000046.
F. Yan, L. Liu, H. Cao, et al., Neonatal colonization of mice with LGG promotes intestinal development and decreases susceptibility to colitis in adulthood, Mucosal Immunol. 10 (2017) 117-127. https://doi.org/10.1038/mi.2016.43.
C. Pagnini, V.D. Corleto, M. Martorelli, et al., Mucosal adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG in the human colonic mucosa: a proof-of-concept study, World J. Gastroenterol. 24 (2018) 4652-4662. https://doi.org/10.3748/wjg.v24.i41.4652.
L. Capurso, Thirty years of Lactobacillus rhamnosus GG: a review, J. Clin. Gastroenterol. 53 (2019) S1-S41. https://doi.org/10.1097/MCG.0000000000001170.
L. Cervantes-Barragan, J.N. Chai, M.D. Tianero, et al., Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells, Science 357 (2017) 806- 810. https://doi.org/10.1126/science.aah5825.
E. Drula, M.L. Garron, S. Dogan, et al., The carbohydrate-active enzyme database: functions and literature, Nucleic Acids Res. 50 (2022) D571-D577. https://doi.org/10.1093/nar/gkab1045.
W. Song, H.X. Sun, C. Zhang, et al., Prophage hunter: an integrative hunting tool for active prophages, Nucleic Acids Res. 47 (2019) W74-W80. https://doi.org/10.1093/nar/gkz380.
Y. Chen, Y. Jin, C. Stanton, et al., Dose-response efficacy and mechanisms of orally administered CLA-producing Bifidobacterium breve CCFM683 on DSS-induced colitis in mice, J. Funct. Foods 75 (2020) 104245. https://doi.org/10.1016/j.jff.2020.104245.
Y. Chen, Y. Jin, C. Stanton, et al., Alleviation effects of Bifidobacterium breve on DSS-induced colitis depends on intestinal tract barrier maintenance and gut microbiota modulation, Eur. J. Nutr. 60 (2021) 369-387. https://doi.org/10.1007/s00394-020-02252-x.
H.F. Steedman, Alcian blue 8GS: a new stain for mucin, Q. J. Microsc. Sci. 91 (1950) 477-479. https://doi.org/10.1242/jcs.s3-91.16.477.
L. Wang, L. Hu, S. Yan, et al., Effects of different oligosaccharides at various dosages on the composition of gut microbiota and short-chain fatty acids in mice with constipation, Food Funct. 8 (2017) 1966-1978. https://doi.org/10.1039/C7FO00031F.
M. Le Barz, N. Daniel, T.V. Varin, et al., In vivo screening of multiple bacterial strains identifies Lactobacillus rhamnosus Lb102 and Bifidobacterium animalis ssp. lactis Bf141 as probiotics that improve metabolic disorders in a mouse model of obesity, FASEB J. 33 (2019) 4921-4935. https://doi.org/10.1096/fj.201801672R.
D. Li, H. Chen, B. Mao, et al., Microbial biogeography and core microbiota of the rat digestive tract, Sci. Rep. 7 (2017) 45840. https://doi.org/10.1038/srep45840.
Y. Aratani, Myeloperoxidase: its role for host defense, inflammation, and neutrophil function, Arch. Biochem. Biophys. 640 (2018) 47-52. https://doi.org/10.1016/j.abb.2018.01.004.
G.X. Zhou, Z.J. Liu, Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease, J. Dig. Dis. 18 (2017) 495-503. https://doi.org/10.1111/1751-2980.12540.
R. Okumura, K. Takeda, Maintenance of intestinal homeostasis by mucosal barriers, Inflamm. Regen. 38 (2018) 5. https://doi.org/10.1186/s41232-018-0063-z.
L. Wang, D.E. Fouts, P. Starkel, et al., Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation, Cell Host Microbe 19 (2016) 227- 239. https://doi.org/10.1016/j.chom.2016.01.003.
F.E.O. Holmberg, J. Pedersen, P. Jorgensen, et al., Intestinal barrier integrity and inflammatory bowel disease: stem cell-based approaches to regenerate the barrier, J. Tissue Eng. Regen. Med. 12 (2018) 923-935. https://doi.org/10.1002/term.2506.
D. Manrique Vergara, M.E. Gonzalez Sanchez, Short chain fatty acids (butyric acid) and intestinal diseases, Nutr. Hosp. 34 (2017) 58-61. https://doi.org/10.20960/nh.1573.
F. van Immerseel, R. Ducatelle, M. de Vos, et al., Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease, J. Med. Microbiol. 59 (2010) 141-143. https://doi.org/10.1099/jmm.0.017541-0.
S. Stojanov, A. Berlec, B. Strukelj, The influence of probiotics on the Firmicutes/Bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease, Microorganisms 8 (2020) 1715. https://doi.org/10.3390/microorganisms8111715.
Q. He, Q. Hou, Y. Wang, et al., Comparative genomic analysis of Enterococcus faecalis: insights into their environmental adaptations, BMC Genomics 19 (2018) 527-527. https://doi.org/10.1186/s12864-018-4887-3.
Z. Liu, F. Liu, W. Wang, et al., Study of the alleviation effects of a combination of Lactobacillus rhamnosus and inulin on mice with colitis, Food Funct. 11 (2020) 3823-3837. https://doi.org/10.1039/c9fo02992c.
W. Panpetch, P. Hiengrach, S. Nilgate, et al., Additional Candida albicans administration enhances the severity of dextran sulfate solution induced colitis mouse model through leaky gut-enhanced systemic inflammation and gut-dysbiosis but attenuated by Lactobacillus rhamnosus L34, Gut Microbes 11 (2020) 465-480. https://doi.org/10.1080/19490976.2019.1662712.
H. Wang, C. Zhou, J. Huang, et al., The potential therapeutic role of Lactobacillus reuteri for treatment of inflammatory bowel disease, Am. J. Transl. Res. 12 (2020) 1569-1583.
G. Wang, S. Huang, S. Cai, et al., Lactobacillus reuteri ameliorates intestinal inflammation and modulates gut microbiota and metabolic disorders in dextran sulfate sodium-induced colitis in mice, Nutrients 12 (2020) 2298. https://doi.org/10.3390/nu12082298.
J.L. Liu, Y.Y. Gao, J. Zhou, et al., Changes in serum inflammatory cytokine levels and intestinal flora in a self-healing dextran sodium sulfate-induced ulcerative colitis murine model, Life Sci. 263 (2020) 118587. https://doi.org/10.1016/j.lfs.2020.118587.
K.J. Maloy, F. Powrie, Intestinal homeostasis and its breakdown in inflammatory bowel disease, Nature 474 (2011) 298-306. https://doi.org/10.1038/nature10208.
L. Zhang, P. Song, X. Zhang, et al., Alpha-glucosidase inhibitors alter gut microbiota and ameliorate collagen-induced arthritis, Front. Pharmacol. 10 (2020) 1684. https://doi.org/10.3389/fphar.2019.01684.
X. Bian, W. Wu, L. Yang, et al., Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice, Front. Microbiol. 10 (2019) 2259. https://doi.org/10.3389/fmicb.2019.02259.
N.O. Kaakoush, Sutterella species, IgA-degrading bacteria in ulcerative colitis, Trends Microbiol. 28 (2020) 519-522. https://doi.org/10.1016/j.tim.2020.02.018.
J. Yang, P. Xiong, L. Bai, et al., The association of altered gut microbiota and intestinal mucosal barrier integrity in mice with heroin dependence, Front. Nutr. 8 (2021) 765414. https://doi.org/10.3389/fnut.2021.765414.
Z. Armstrong, K. Mewis, F. Liu, et al., Metagenomics reveals functional synergy and novel polysaccharide utilization loci in the Castor canadensis fecal microbiome, ISME J. 12 (2018) 2757-2769. https://doi.org/10.1038/s41396-018-0215-9.
A. Gulnaz, J. Nadeem, J.H. Han, et al., Lactobacillus SPS in reducing the risk of diabetes in high-fat diet-induced diabetic mice by modulating the gut microbiome and inhibiting key digestive enzymes associated with diabetes, Biol. Basel. 10 (2021) 348. https://doi.org/10.3390/biology10040348.
M. Wlodarczyk, K. Slizewska, R. Barczynska, et al., Effects of resistant dextrin from potato starch on the growth dynamics of selected co-cultured strains of gastrointestinal bacteria and the activity of fecal enzymes, Nutrients 14 (2022) 2158. https://doi.org/10.3390/nu14102158.
A. Nadeem, L.M. Wahl, Prophage as a genetic reservoir: promoting diversity and driving innovation in the host community, Evolution 71 (2017) 2080-2089. https://doi.org/10.1111/evo.13287.
T. Olszak, A. Latka, B. Roszniowski, et al., Phage life cycles behind bacterial biodiversity, Curr. Med. Chem. 24 (2017) 3987-4001. https://doi.org/10.2174/0929867324666170413100136.
J.H. Oh, X.B. Lin, S. Zhang, et al., Prophages in Lactobacillus reuteri are associated with fitness trade-offs but can increase competitiveness in the gut ecosystem, Appl. Environ. Microbiol. 86 (2020) e01922-19. https://doi.org/10.1128/AEM.01922-19.
1179
Views
170
Downloads
0
Crossref
0
Web of Science
0
Scopus
0
CSCD
Altmetrics
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
京公网安备11010802044758号